2025
An international perspective on the future of systemic sclerosis research
Abraham D, Black C, Denton C, Distler J, Domsic R, Feghali-Bostwick C, Gourh P, Hinchcliff M, Kolling F, Kuwana M, Lafyatis R, Landegren U, Mahoney J, Martin J, Matucci-Cerinic M, McMahan Z, Mora A, Mouthon L, Rabinovitch M, Rojas M, Rubin K, Trojanowska M, Varga J, Whitfield M, Gabrielli A, Krieg T. An international perspective on the future of systemic sclerosis research. Nature Reviews Rheumatology 2025, 21: 174-187. PMID: 39953141, DOI: 10.1038/s41584-024-01217-2.Peer-Reviewed Original ResearchConceptsSystemic sclerosisSystemic sclerosis researchHistory of systemic sclerosisInnovative clinical trial designsSystemic autoimmune diseaseEarly pathogenetic eventClinical trial designCollaborative global effortAutoimmune phenomenaImprove patient outcomesDisease activityMicrovascular dysfunctionClinical historyEmergency therapyAutoimmune diseasesDisease-modifying treatmentsTissue fibrosisSingle-cell RNA sequencingClinical heterogeneityEffective disease-modifying treatmentsPersonalized therapyAnimal modelsComplex pathogenesisEffective treatmentNext-generation sequencingCollagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis.
Ahmad A, Ghim M, Kukreja G, Neishabouri A, Zhang Z, Li J, Salarian M, Toczek J, Gona K, Hedayatyanfard K, Morrison T, Zhang J, Huang Y, Liu C, Yu S, Sadeghi M. Collagen Hybridizing Peptide-Based Radiotracers for Molecular Imaging of Collagen Turnover in Pulmonary Fibrosis. Journal Of Nuclear Medicine 2025, 66: 425-433. PMID: 39915119, PMCID: PMC11876730, DOI: 10.2967/jnumed.124.268832.Peer-Reviewed Original ResearchConceptsPulmonary fibrosisTracer uptakeLung uptakeMurine model of pulmonary fibrosisModel of pulmonary fibrosisMice 3 wkEffect of antifibrotic therapyCollagen turnoverInterstitial lung diseaseClinical diagnostic methodsSPECT/CT imagingHybrid tracersLung histologyAntifibrotic therapyControl miceDisease activityMurine modelLung diseaseMice 8Tissue fibrosisPatient managementLiver uptakeSPECT/CTFibrosisSPECT imagesDistinctive Macrophage Migration Inhibitory Factor Receptor Patterns and Soluble Biomarkers in Rheumatoid Arthritis: Unveiling Key Associations with Disease Activity
Sánchez-Zuno G, Bucala R, Hernández-Bello J, Palafox-Sánchez C, Vizcaíno-Quirarte A, Muñoz-Valle J. Distinctive Macrophage Migration Inhibitory Factor Receptor Patterns and Soluble Biomarkers in Rheumatoid Arthritis: Unveiling Key Associations with Disease Activity. Journal Of Interferon & Cytokine Research 2025, 45: 99-106. PMID: 39914814, PMCID: PMC12021775, DOI: 10.1089/jir.2024.0184.Peer-Reviewed Original ResearchConceptsMigration inhibitory factorMigration inhibitory factor levelsDisease activityRA patientsControl subjectsRheumatoid arthritisLevels of migration inhibitory factorSerum levels of CXCL12Levels of CXCL12Serum of RA patientsModerate disease activityMembranous expression patternRheumatoid factor titerMIF levelsCXCL12 levelsSerum levelsCXCL8 levelsSoluble biomarkersTreatment protocolsPattern of expressionSerum CXCL8PatientsReceptor patternsClinical biomarkersInhibitory factorTranslocating gut pathobiont Enterococcus gallinarum induces TH17 and IgG3 anti-RNA–directed autoimmunity in mouse and human
Gronke K, Nguyen M, Fuhrmann H, Santamaria de Souza N, Schumacher J, Pereira M, Löschberger U, Brinkhege A, Becker N, Yang Y, Sonnert N, Leopold S, Martin A, von Münchow-Klein L, Pessoa Rodrigues C, Cansever D, Hallet R, Richter K, Schubert D, Daniel G, Dylus D, Forkel M, Schwinge D, Schramm C, Redanz S, Lassen K, Manfredo Vieira S, Piali L, Palm N, Bieniossek C, Kriegel M. Translocating gut pathobiont Enterococcus gallinarum induces TH17 and IgG3 anti-RNA–directed autoimmunity in mouse and human. Science Translational Medicine 2025, 17: eadj6294. PMID: 39908347, DOI: 10.1126/scitranslmed.adj6294.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusAutoimmune diseasesToll-like receptor 8Gut pathobiontsHuman adaptive immune responseLong-term sequelaeAdaptive immune responsesHuman T cellsChronic autoimmune diseaseHuman monocyte activationContribution to autoimmunityAutoimmune hepatitisAutoantibody titersAnti-<i>E.Autoimmune pathophysiologyLupus modelT-helperLifelong immunosuppressionTargeted therapyT cellsDisease activityLupus erythematosusAutoantibody responseMonocyte activationImmune responseTranscriptome signature in the blood of neuromyelitis optica spectrum disorder under steroid tapering
Yamamura R, Kinoshita M, Yasumizu Y, Yata T, Kihara K, Motooka D, Shiraishi N, Sugiyama Y, Beppu S, Murata H, Koizumi N, Sano I, Koda T, Okuno T, Mochizuki H. Transcriptome signature in the blood of neuromyelitis optica spectrum disorder under steroid tapering. Frontiers In Immunology 2025, 16: 1508977. PMID: 39963140, PMCID: PMC11830620, DOI: 10.3389/fimmu.2025.1508977.Peer-Reviewed Original ResearchConceptsNeuromyelitis optica spectrum disorderPeripheral blood mononuclear cellsNeuromyelitis optica spectrum disorder patientsSteroid taperIL-10Steroid dosagePeripheral blood transcriptomic signatureDecreased expressionInterferon signalingTransform treatment strategiesIndicator of disease activityNon-relapsing patientsAnti-AQP4 antibodyDisease activity biomarkersTranscriptomic signaturesBlood mononuclear cellsAdvent of biologicsBlood transcriptomic signaturesAnti-inflammatory pathwayIL-10 signalingRelapsed patientsImmune signaturesSteroid reductionDisease activityActivation biomarkersGlobal Delphi consensus on treatment goals for generalized pustular psoriasis
Barker J, Casanova E, Choon S, Foley P, Fujita H, Gonzalez C, Gooderham M, Marrakchi S, Puig L, Romiti R, Thaçi D, Zheng M, Strober B, Magariños G, Reich A, Nakano J, Gao X, Zhang F, Sayed M, Welzel J, Gisondi P, Yaacob Y, Prignano F, Tada Y, Jo S, van der Kerkhof P, Casanova E, Rivera R, Schmitt-Egenolf M, Tsai T, Baskan E, Burden D, Mostaghimi A, Reisner D, Eyerich K, Stratigos A, Pavlovsky L, Quintero D, Imafuku S, Becker J, Affandi A, Cortés C, Carrascosa J, Wiseman M, Viguier M, Bhutani T. Global Delphi consensus on treatment goals for generalized pustular psoriasis. British Journal Of Dermatology 2025, 192: 706-716. PMID: 39844356, DOI: 10.1093/bjd/ljae491.Peer-Reviewed Original ResearchConceptsLong-term treatment goalsGeneralized pustular psoriasisPatient perspectiveTreatment goalsDelphi panelPerspectives of patientsPatient-centred approachPustular psoriasisTreatment of generalized pustular psoriasisGPP treatmentQuality of lifePrevention of life-threatening complicationsManagement of comorbiditiesPatient participationPatient representativesLife-threatening complicationsTailored treatment planSymptom burdenShort-term treatment goalsDelphi consensusNeutrophilic inflammatory diseasesSymptom controlSteering CommitteeSystematic literature reviewDisease activityA Real-World Prospective Multiple Sclerosis Pregnancy Registry in the United States
Houtchens M, Manieri M, Mahlanza T, Pol-Patil J, Klawiter E, Solomon A, Lathi E, Katz J, Ionete C, Morales I, Severson C, Zurawski J, Stankiewicz J, Cabot A, Sadovnick A. A Real-World Prospective Multiple Sclerosis Pregnancy Registry in the United States. Neurology Clinical Practice 2025, 15: e200425. PMID: 39810912, PMCID: PMC11727603, DOI: 10.1212/cpj.0000000000200425.Peer-Reviewed Original ResearchDisease-modifying therapiesHigh-risk pregnanciesPregnancy RegistryPregnancy outcomesMultiple sclerosisConception attemptsTreated with disease-modifying therapiesBaseline Expanded Disability Status ScaleAdverse pregnancy outcomesClinical disease activityCourse of MSExpanded Disability Status ScaleLonger-term developmental outcomesYears of postpartumReproductive-age womenAssisted reproductive technologyDisability Status ScalePeripartum complicationsTime of conceptionObstetric complicationsPostpartum exacerbationPostpartum relapseIntrapartum periodDisease activityProportion of participantsAcid sphingomyelinase deficiency and Gaucher disease: Underdiagnosed and often treatable causes of hepatomegaly, splenomegaly, and low HDL cholesterol in lean individuals
Mistry P, Cassiman D, Jones S, Lachmann R, Lukina E, Prada C, Wasserstein M, Thurberg B, Foster M, Patel R, Underhill L, Peterschmitt M. Acid sphingomyelinase deficiency and Gaucher disease: Underdiagnosed and often treatable causes of hepatomegaly, splenomegaly, and low HDL cholesterol in lean individuals. Hepatology Communications 2025, 9: e0621. PMID: 39774103, PMCID: PMC11717527, DOI: 10.1097/hc9.0000000000000621.Peer-Reviewed Original ResearchConceptsGaucher disease type 1Acid sphingomyelinase deficiencyHDL cholesterolSphingomyelinase deficiencyDifferential diagnosis of patientsBiomarkers of disease activityLipoprotein phenotypeLower body mass indexMean HDL cholesterolLow HDL cholesterolLiver function testsDiagnosis of patientsBody mass indexModerate hepatosplenomegalySpleen volumeLipid abnormalitiesLow HDLDiagnostic delayIrreversible complicationsLiver volumeLyso-sphingomyelinMultisystemic manifestationsDisease activityLDL cholesterolDifferential diagnosisPtpA protein from Mycobacterium avium subsp. paratuberculosis as a potential marker of rheumatoid arthritis in humans
Hernández-Bello J, Bach H, Cerpa-Cruz S, Sánchez-Zuno G, Hernández-Gutiérrez R, Nicoletti F, Saraceno A, Muñoz-Valle J. PtpA protein from Mycobacterium avium subsp. paratuberculosis as a potential marker of rheumatoid arthritis in humans. PLOS ONE 2025, 20: e0316727. PMID: 39752467, PMCID: PMC11698356, DOI: 10.1371/journal.pone.0316727.Peer-Reviewed Original ResearchConceptsMycobacterium avium subspecies paratuberculosisControl subjectsVirulence factorsRA patientsBattery of virulence factorsRheumatoid arthritisProtein tyrosine phosphatase ADisease activityPhago-lysosome fusionModerate to high disease activityHigh disease activityDisease Activity ScoreMale control subjectsIndirect ELISA methodMycobacterium avium subspecies paratuberculosis infectionMycobacterium avium subspPhosphatase AMarkers of rheumatoid arthritisIntracellular pathogensPTPAMedian ODActivity scoreProteinELISA methodPatients
2024
Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy Support
Gottesman S, Xiao K, Nguyen H, Hernandez E, Saweris E, Jagannathan P, Jafri F, Davis J, Tong K, Tang Z, Gaidos J, Feagins L. Higher Rates of Delay in Starting Advanced Inflammatory Bowel Disease Therapies Linked to Insurance Delays, Intravenous Infusions, and Lack of Pharmacy Support. Clinical And Translational Gastroenterology 2024, 16: e00808. PMID: 39718220, PMCID: PMC11932631, DOI: 10.14309/ctg.0000000000000808.Peer-Reviewed Original ResearchConceptsAdvanced therapiesRisk factorsMulticenter studyMulticenter study of patientsInflammatory bowel disease therapyStudy of patientsAdult inflammatory bowel diseasePatient-related factorsIntravenous drug deliverySmall molecule therapiesLogistic regression analysisInflammatory bowel diseaseBaseline demographicsDisease activityIntravenous infusionMolecule therapiesDisease characteristicsGastroenterology practiceTherapyBowel diseaseInsurance denialPatientsDoseIntravenous inductionCare teamCorrelation Between Pain, Disease Activity, and Rheumatoid Factor Positivity in Patients with Chikungunya Arthritis
Amaral J, Schoen R, Bingham C, Firmino P, Cândido E. Correlation Between Pain, Disease Activity, and Rheumatoid Factor Positivity in Patients with Chikungunya Arthritis. The Yale Journal Of Biology And Medicine 2024, 97: 417-422. PMID: 39703605, PMCID: PMC11650909, DOI: 10.59249/hgxw4816.Peer-Reviewed Original ResearchConceptsVisual analog scaleChikungunya arthritisDisease activityDAS28-ESRRheumatoid factorPain visual analog scaleChikungunya feverDisease Activity ScoreRheumatoid factor positivityDisease activity indexChikungunya virusSignificantly with disease activityAcute viral diseasePain intensityAnalog scaleRetrospective cohortPain riskProspective cohortFactor positivityImproved therapiesActivity scoreClinical evaluationJoint symptomsPainAcute phaseEndoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel
Panel T, Shen B, Abreu M, Cohen E, Farraye F, Fischer M, Feuerstadt P, Kapur S, Ko H, Kochhar G, Liu X, Mahadevan U, McBride D, Navaneethan U, Regueiro M, Ritter T, Sharma P, Lichtenstein G. Endoscopic diagnosis and management of adult inflammatory bowel disease: a consensus document from the American Society for Gastrointestinal Endoscopy IBD Endoscopy Consensus Panel. Gastrointestinal Endoscopy 2024, 101: 295-314. PMID: 39425706, DOI: 10.1016/j.gie.2024.08.034.Peer-Reviewed Original ResearchInflammatory bowel diseaseInflammatory bowel disease specialistsAssessment of treatment responseBowel diseaseClinical practice patternsConsensus documentMonitoring of disease activityAdult inflammatory bowel diseaseDysplasia surveillancePractice patternsGI pathologistsEndoscopic aspectDisease activityEndoscopic managementPostoperative evaluationConsensus panelTreatment responseInterventional therapyEndoscopic diagnosisIBD managementDiagnosisDiseaseValidation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials
Pulaski H, Mehta S, Manigat L, Kaufman S, Hou H, Nalbantoglu I, Zhang X, Curl E, Taliano R, Kim T, Torbenson M, Glickman J, Resnick M, Patel N, Taylor C, Bedossa P, Montalto M, Beck A, Wack K. Validation of a whole slide image management system for metabolic‐associated steatohepatitis for clinical trials. The Journal Of Pathology Clinical Research 2024, 10: e12395. PMID: 39294925, PMCID: PMC11410674, DOI: 10.1002/2056-4538.12395.Peer-Reviewed Original ResearchConceptsClinical trialsAssessment of disease activityOverall percent agreementLiver biopsyDisease activityPathological assessmentWashout periodHistological assessmentEndpoint assessmentGold standardPercent agreementScoring systemExpert pathologistsSteatohepatitisAverage agreementDigital scoresPathologistsTrialsGastrointestinal disease in systemic sclerosis: the neglected organ system?
McMahan Z, Pandolfino J, Perlman H, Del Galdo F, Hinchcliff M. Gastrointestinal disease in systemic sclerosis: the neglected organ system? Current Opinion In Rheumatology 2024, 36: 374-378. PMID: 39193877, PMCID: PMC11588520, DOI: 10.1097/bor.0000000000001052.Peer-Reviewed Original ResearchSystemic sclerosisClinical trial endpointsInflammatory bowel diseaseTrial endpointsAssessment of disease activityRisk stratification methodsGastrointestinal (GIDisease activityRisk stratificationEffective therapyImmune responseBowel diseaseDisease pathogenesisTherapeutic interventionsGastrointestinal diseasesOrgan systemsDiseaseMultidisciplinary teamPathogenesisFunctional studiesGut microbiomeEndpointSclerosisRevisiting the Pattern of Loss of β-Cell Function in Preclinical Type 1 Diabetes.
Martino M, Galderisi A, Evans-Molina C, Dayan C. Revisiting the Pattern of Loss of β-Cell Function in Preclinical Type 1 Diabetes. Diabetes 2024, 73: 1769-1779. PMID: 39106185, DOI: 10.2337/db24-0163.Peer-Reviewed Original ResearchB cell functionBeta cell lossType 1 diabetesLoss of B-cell functionCell lossOral glucose tolerance testPreclinical type 1 diabetesEarly stage diseaseBeta cell destructionTime of diagnosisDestruction of B cellsGlucose tolerance testMonths prior to clinical diagnosisAntibody positivityStage diseaseDisease activityAutoimmune destructionB cellsDisease accelerationInsulin therapyTolerance testInsulin secretionSubmaximal stimuliCell destructionGlucose controlImpact of Food Avoidance on Vitamin D Intake in Inflammatory Bowel Disease Patients
Almahmoud E, Larson D, Gaidos J, Feagins L, Burgermaster M. Impact of Food Avoidance on Vitamin D Intake in Inflammatory Bowel Disease Patients. Journal Of Nutrition Education And Behavior 2024, 56: s62-s63. DOI: 10.1016/j.jneb.2024.05.144.Peer-Reviewed Original ResearchVitamin D intakeAssociated with vitamin D intakeInflammatory bowel diseaseD intakeInflammatory bowel disease patientsFlare-upVitamin DIntake of vitamin DCross-sectional studyFood avoidanceVitamin D. Vitamin D deficiencyInflammatory bowel disease centerChronic inflammatory diseaseDiet recallMeans foodStudy designAcademic hospitalD deficiencyDisease activityGastrointestinal symptomsInflammatory diseasesParticipantsBowel diseaseDietary restrictionDisease patientsA unified metric of human immune health
Sparks R, Rachmaninoff N, Lau W, Hirsch D, Bansal N, Martins A, Chen J, Liu C, Cheung F, Failla L, Biancotto A, Fantoni G, Sellers B, Chawla D, Howe K, Mostaghimi D, Farmer R, Kotliarov Y, Calvo K, Palmer C, Daub J, Foruraghi L, Kreuzburg S, Treat J, Urban A, Jones A, Romeo T, Deuitch N, Moura N, Weinstein B, Moir S, Ferrucci L, Barron K, Aksentijevich I, Kleinstein S, Townsley D, Young N, Frischmeyer-Guerrerio P, Uzel G, Pinto-Patarroyo G, Cudrici C, Hoffmann P, Stone D, Ombrello A, Freeman A, Zerbe C, Kastner D, Holland S, Tsang J. A unified metric of human immune health. Nature Medicine 2024, 30: 2461-2472. PMID: 38961223, DOI: 10.1038/s41591-024-03092-6.Peer-Reviewed Original ResearchClinically healthy individualsHealthy individualsImmune cell frequenciesImmune healthInflammatory biomarkers C-reactive proteinC-reactive proteinBiomarkers C-reactive proteinResponse to immunizationAntibody response to immunizationInflammatory disease statesImmune pathologyDisease activityTreatment responseAntigenic stimulationImmune consequencesClinical dataImmunological pathwaysHealthy controlsCell frequencyInterleukin-6Nonimmunologic diseasesImmune diseasesMonogenic diseasesMonogenic conditionsMedication usePractical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease
Guiot J, Miedema J, Cordeiro A, De Vries-Bouwstra J, Dimitroulas T, Søndergaard K, Tzouvelekis A, Smith V. Practical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease. Autoimmunity Reviews 2024, 23: 103582. PMID: 39074630, DOI: 10.1016/j.autrev.2024.103582.Peer-Reviewed Original ResearchInterstitial lung diseaseConnective tissue diseaseConnective tissue disease-related interstitial lung diseaseLung diseaseTissue diseaseCTD-ILDJourney of patientsProgression of interstitial lung diseaseManagement of CTD-ILDComplication of connective tissue diseasesFollow-up of patientsIdentification of interstitial lung diseaseHeterogeneous group of diseasesDisease activity of patientsActivity of patientsPulmonary function testsInternational expert panelGroup of diseasesMultidisciplinary teamExpert panelProgressive diseaseChest radiographyDisease activityClinical examinationFollow-upDisruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus
Arends E, Zlei M, Tipton C, Cotic J, Osmani Z, de Bie F, Kamerling S, van Maurik A, Dimelow R, Gregan Y, Fox N, Rabelink T, Roth D, Sanz I, van Dongen J, van Kooten C, Teng Y. Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus. Rheumatology 2024, 63: 2387-2398. PMID: 38775637, PMCID: PMC11371378, DOI: 10.1093/rheumatology/keae286.Peer-Reviewed Original ResearchMemory B cellsSystemic lupus erythematosusCirculating memory B cellsB cellsLupus nephritisLupus erythematosusAutoreactive memory B cellsMemory B cell subsetsSLE disease activityMemory B cell phenotypeEfficacy of belimumabSerologically active patientsHigh-sensitivity flow cytometryNaive B cellsB-cell traffickingB cell activationInhibition of B cell activationRetrospective meta-analysisBelimumab initiationIntravenous belimumabSubcutaneous belimumabBelimumabDisease activityLymphocyte traffickingAutoimmune diseasesComorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis
Crowson C, Atkinson E, Kronzer V, Kimbrough B, Arment C, Peterson L, Wright K, Mason T, Bekele D, Davis J, Myasoedova E. Comorbidity clusters in patients with rheumatoid arthritis identify a patient phenotype with a favourable prognosis. Annals Of The Rheumatic Diseases 2024, 83: 556-563. PMID: 38331589, PMCID: PMC11017091, DOI: 10.1136/ard-2023-225093.Peer-Reviewed Original ResearchRA disease activityStandardised mortality ratioPrevalence of depressionRheumatoid arthritisPopulation-based studyEight-county regionDisease activityComorbidity patternsMortality ratioDisease-modifying antirheumatic drugsPrevalence dateVital statusCluster patientsLatent class analysisComorbidity clustersAssess mortalityGeneral populationRA prognosisOlder patientsAntirheumatic drugsComorbiditiesPatient phenotypesClass analysisComorbidityPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply